Skip to main content
SpringerLink
Log in

Management of Gastric Neuroendocrine Tumors

  • Chapter
Abdominal Neuroendocrine Tumors

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 970 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thomas D, Tsolakis AV, Grozinsky-Glasberg S et al (2013) Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 168(2):185–193

    Article  CAS  PubMed  Google Scholar 

  2. Sato Y, Hashimoto S, Mizuno K et al (2016) Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol 22(30):6817–6828

    Article  PubMed  PubMed Central  Google Scholar 

  3. Postlewait LM, Baptiste GG, Ethun CG et al (2016) A 15-year experience with gastric neuroendocrine tumors: does type make a difference? J Surg Oncol 114(5):576–580

    Article  PubMed  Google Scholar 

  4. Kulke MH, Shah MH, Benson AB et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13(1):78–108

    Article  CAS  PubMed  Google Scholar 

  5. Basuroy R, Srirajaskanthan R, Prachalias A et al (2014) Review article: the investigation and management of gastric neuroendocrine tumors. Aliment Pharmacol Ther 39(10): 1071–1084

    Article  CAS  PubMed  Google Scholar 

  6. Delle Fave G, O’Toole D, Sundin A et al (2016) ENETS Consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103(2): 119–124

    Article  CAS  PubMed  Google Scholar 

  7. AIOM — Associazione Italiana di Oncologia Medica (2015) Linee guida: Neoplasie neuroendocrine. In condivisione con It.a.net — Italian Association for Neuroendocrine Tumors. http://ita-net.org/system/attachments/files/000/000/037/original/2015_LG_AIOM_Neuroendocrini.pdf?1460563182

  8. Suzuki S, Ishii N, Uemura M et al (2012) Endoscopic submucosal dissection (ESD) for gastrointestinal carcinoid tumors. Surg Endosc 26(3):759–763

    Article  PubMed  Google Scholar 

  9. Li QL, Zhang YQ, Chen WF et al (2012) Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol 18(40):5799–5806

    Article  PubMed  PubMed Central  Google Scholar 

  10. Saito Y, Otake Y, Sakamoto T et al (2013) Indications for and technical aspects of colorectal endoscopic submucosal dissection. Gut Liver 7(3):263–269

    Article  PubMed  PubMed Central  Google Scholar 

  11. Guillem P (2005) Gastric carcinoid tumours. Is there a place for antrectomy? Ann Chir 130(5):323–326

    CAS  Google Scholar 

  12. Gladdy RA, Strong VE, Coit D et al (2009) Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol 16(11):3154–3160

    Article  PubMed  Google Scholar 

  13. Ozao-Choy J, Buch K, Strauchen JA et al (2010) Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 162(1):22–25

    Article  PubMed  Google Scholar 

  14. Bordi C, Azzoni C, Pilato FP et al (1993) Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regul Pept 47(3):307–318

    Article  CAS  PubMed  Google Scholar 

  15. Ferraro G, Annibale B, Marignani M et al (1996) Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 81(2):677–683

    CAS  PubMed  Google Scholar 

  16. Campana D, Nori F, Pezzilli R et al (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15(1):337–342

    Article  CAS  PubMed  Google Scholar 

  17. Fykse V, Sandvik AK, Qvigstad G et al (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39(7):621–628

    Article  CAS  PubMed  Google Scholar 

  18. Jianu CS, Fossmark R Syversen U et al (2011) Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 46(4):456–463

    Article  PubMed  Google Scholar 

  19. Campana D, Ravizza D, Ferolla P et al (2016) Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 51(1):131–139

    Article  CAS  PubMed  Google Scholar 

  20. La Rosa S, Vanoli A (2014) Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Phatol 67(11):938–948

    Google Scholar 

  21. Arigami T, Uenosono Y, Yanagita S et al (2016) Sentinel node navigation surgery for gastroduodenal neuroendocrine tumors: two case reports. Medicine (Baltimore) 95(26):e4063

    Article  Google Scholar 

  22. Carlini M, Carboni F, Petric M et al (2002) Sentinel node in gastric cancer surgery. J Exp Clin Cancer Res 21(4):469–473

    CAS  PubMed  Google Scholar 

  23. Takata A, Nakajima K, Kurokawa Y et al (2014) Single-incision laparoscopic partial gastrectomy for gastric submucosal tumors without compromising transumbilical stapling. Asian J Endoscopic Surg 7(1):25–30

    Article  Google Scholar 

  24. Kanaji S, Nakamura T, Yamamoto M et al (2015) Successful laparoscopic gastric resection and safe introduction of a single-incision technique for gastric submucosal tumors located near the esophagogastric junction. Surg Today 45(2):209–214

    Article  PubMed  Google Scholar 

  25. Tomassetti P, Migliori M, Caletti GC et al (2000) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343(8):551–554

    Article  CAS  PubMed  Google Scholar 

  26. Kitano M, Norlen P, Ding XQ et al (2000) Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022. Br J Pharmacol 130(3):699–705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Boyce M, Moore AR, Sagatun L et al (2017) Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol 83(3):466–475

    Article  CAS  PubMed  Google Scholar 

  28. Fossmark R, Sordal O, Jianu CS et al (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 36(11–12):1067–1075

    Article  CAS  PubMed  Google Scholar 

  29. Moore AR, Boyce M, Steele IA et al (2013) Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 8(10):e76462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. YF476 and Type II Gastric Carcinoids — A pilot trial of YF476, a gastrin antagonist, in patients with type II gastric carcinoids associated with Zollinger-Ellison syndrome. ClinicalTrials. gov Identifier: NCT02454075. https://clinicaltrials.gov/ct2/show/NCT02454075

  31. Tan H (2016) Advances in the diagnosis and treatment of gastric neuroendocrine neoplasm. Transl Gastroenterol Hepatol 1:87

    Article  PubMed  PubMed Central  Google Scholar 

  32. Modlin IM, Lye KD, Kidd M (2003) Carcinoid tumors of the stomach. Surg Oncol 12(2):153–172

    Article  PubMed  Google Scholar 

  33. Scherubl H, Cadiot G, Jensen RT et al (2010) Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 42(8):664–671

    Article  CAS  PubMed  Google Scholar 

  34. Kwon YH, Jeon SW, Kim GH et al (2013) Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 19(46):8703–8708

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ravizza D, Fiori G, Trovato C et al (2007) Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis 39(6):537–543

    Article  CAS  PubMed  Google Scholar 

  36. Herrera-Almario G, Patane M, Sarkaria I, Strong VE (2016) Initial report of near-infrared fluorescence imaging as an intraoperative adjunct for lymph node harvesting during robot-assisted laparoscopic gastrectomy. J Surg Oncol 113(7):768–770

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kunz PL, Reidy-Lagunes D, Anthony LB et al (2013) Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42(4):557–577

    Article  PubMed  PubMed Central  Google Scholar 

  38. Bordi C, Falchetti A, Azzoni C et al (1997) Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 21(9):1075–1082

    Article  CAS  PubMed  Google Scholar 

  39. Lewkowicz E, Trofimiuk-Müldner M, Wysocka K et al (2015) Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center. Pol Arch Med Wewn 125(5):337–346

    PubMed  Google Scholar 

  40. La Rosa S, Inzani F, Vanoli A et al (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 42(10): 1373–1384

    Article  PubMed  Google Scholar 

  41. Ishida M, Sekine S, Fukagawa T et al (2013) Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol 37(7):949–959

    Article  PubMed  Google Scholar 

  42. Yang M, Tian BL, Zhang Y et al (2014) Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. Pancreas 43(7): 1003–1008

    Article  PubMed  Google Scholar 

  43. Kim BS, Park YS, Yook JH et al (2015) Differing clinical courses and prognoses in patients with gastric neuroendocrine tumors based on the 2010-WHO classification scheme. Medicine (Baltimore) 94(44):e1748

    Article  Google Scholar 

  44. Hijioka S, Hosoda W, Mizuno N et al (2015) Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol 50(5):564–572

    Article  CAS  PubMed  Google Scholar 

  45. Richards D, Davis D, Yan P, Guha S (2011) Unusual case of small cell gastric carcinoma: case report and literature review. Dig Dis Sci 56(4):951–957

    Article  PubMed  Google Scholar 

  46. Huang J, Zhou Y, Zhao X et al (2012) Primary small cell carcinoma of the stomach: an experience of two decades (1990–2011) in a Chinese cancer institute. J Surg Oncol 106(8):994–998

    Article  PubMed  Google Scholar 

  47. Liu DJ, Fu XL, Liu W et al (2107) Clinicophatological, treatment and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol 23(3):516–524

    Article  Google Scholar 

  48. Shen C, Chen H, Chen H et al (2016) Surgical treatment and prognosis of gastric neuroendocrine neoplasm: a single-center experience. BMC Gastroenterology 16:111

    Article  PubMed  PubMed Central  Google Scholar 

  49. Oberg K, Akerström G, Rindi G, Jelic S (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v223–v227

    Article  PubMed  Google Scholar 

  50. Brennan SM, Gregory DL, Stillie A et al (2010) Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 116(4):888–895

    Article  PubMed  Google Scholar 

  51. Li AF, Hsu HS, Hsu CY et al (2010) A 20-year retrospective study of small-cell carcinomas in Taiwan. J Surg Oncol 102(5):497–502

    Article  PubMed  Google Scholar 

  52. Brenner B, Shah MA, Gonen M et al (2004) Small-cell carcinoma of the gastrointestinal tract: A retrospective study of 64 cases. Br J Cancer 90(9): 1720–1726

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Pavel M, O’Toole D, Costa F et al (2016) ENETS Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185

    Article  CAS  PubMed  Google Scholar 

  54. Garcia-Carbonero R, Sorbye H, Baudin E et al (2016) ENETS Consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103(2):186–194

    Article  CAS  PubMed  Google Scholar 

  55. Sorbye H, Strosberg J, Baudin E et al (2014) Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120(18):2814–2823

    Article  CAS  PubMed  Google Scholar 

  56. Sorbye H, Welin S, Langer SW et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24(1):152–160

    Article  CAS  PubMed  Google Scholar 

  57. Ansell SM, Pitot HC, Burch PA et al (2001) A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91(8):1543–1548

    Article  CAS  PubMed  Google Scholar 

  58. Kulke MH, Kim H, Clark JW et al (2004) A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101(5):934–939

    Article  CAS  PubMed  Google Scholar 

  59. Chan JA, Zhu AX, Stuart K et al (2010) Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol 66(5):961–968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ansell SM, Mahoney MR, Green EM, Rubin J (2004) Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 27(3):232–235

    Article  CAS  PubMed  Google Scholar 

  61. Apostolidis L, Bergmann F, Jager D, Winkler EC (2016) Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 5(9):2261–2267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Araki T, Takashima A, Hamaguchi T et al (2016) Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs 27(8):794–799

    Article  CAS  PubMed  Google Scholar 

  63. Noro H, Hirao T, Takaichi S et al (2016) Pathological complete response in a case of advanced esophageal cancer with widespread lymph node metastases treated using preoperative chemotherapy with docetaxel, cisplatin, and 5-FU(DCF therapy). Gan To Kagaku Ryoho 43(12):2178–2180

    PubMed  Google Scholar 

  64. Hadoux J, Malka D, Planchard D et al (2015) Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 22(3):289–298

    Article  CAS  PubMed  Google Scholar 

  65. Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 11 (20):4617–4622

    Article  Google Scholar 

  66. Ramage JK, Ahmed A, Ardill J et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1):6–32

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of General Surgery S. Eugenio Hospital, Rome, Italy

    Massimo Carlini

Authors
  1. Massimo Carlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Apa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Spoletini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michele Grieco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marialuisa Appetecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesca Rota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Salvatore Palazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Salvatore Turano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Carlini .

Editor information

Editors and Affiliations

  1. Department of Surgery, Division of General Surgery, S. Eugenio Hospital, Rome, Italy

    Massimo Carlini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Italia

About this chapter

Cite this chapter

Carlini, M. et al. (2018). Management of Gastric Neuroendocrine Tumors. In: Carlini, M. (eds) Abdominal Neuroendocrine Tumors. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-3955-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-3955-1_10

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-3954-4

  • Online ISBN: 978-88-470-3955-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation